Vividion launches with $50M Series A

February 03, 2017

Share:

Biotechnology | San Diego, CA | Series A

Biotech Vividion Therapeutics is the developer of a drug discovery platform designed to bring new treatments to patients with serious illnesses. The company’s technology, spun out of a lab at Scripps Research Institute, makes the set of proteins expressed in human cells accessible. As part of the financing, Tom Daniel will join Vividion’s board as executive chairman.